Castle Biosciences (NASDAQ: CSTL) is one of 29 public companies in the “Medical laboratories” industry, but how does it compare to its competitors? We will compare Castle Biosciences to similar companies based on the strength of its earnings, valuation, dividends, risk, institutional ownership, analyst recommendations and profitability.
This is a breakdown of current recommendations for Castle Biosciences and its competitors, as provided by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Castle Biosciences Competitors||236||801||981||71||2.42|
This table compares Castle Biosciences and its competitors’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Castle Biosciences Competitors||-122.08%||-87.84%||-28.65%|
Earnings and Valuation
This table compares Castle Biosciences and its competitors revenue, earnings per share and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|Castle Biosciences||$51.87 million||$5.28 million||-34.69|
|Castle Biosciences Competitors||$1.03 billion||$53.91 million||35.05|
Castle Biosciences’ competitors have higher revenue and earnings than Castle Biosciences. Castle Biosciences is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.
Insider & Institutional Ownership
29.7% of Castle Biosciences shares are owned by institutional investors. Comparatively, 51.0% of shares of all “Medical laboratories” companies are owned by institutional investors. 14.2% of shares of all “Medical laboratories” companies are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
Castle Biosciences competitors beat Castle Biosciences on 7 of the 12 factors compared.
About Castle Biosciences
Castle Biosciences, Inc., a commercial-stage dermatological cancer, develops and commercializes diagnostic and prognostic tests for cancers. Its lead product is DecisionDx-Melanoma, a multi-gene expression profile (GEP) test to identify stage I and II patients at high risk of metastasis based on biological information from 31 genes within their tumor tissue. The company also offers DecisionDx-UM test, a proprietary GEP test that predicts the risk of metastasis for patients with uveal melanoma, a rare eye cancer; and two late-stage proprietary products in development, which address cutaneous squamous cell carcinoma and suspicious pigmented lesions, which are indications with high clinical need in dermatological cancer. It offers test services through physicians, physician assistants, and nurse practitioners. The company was founded in 2007 and is headquartered in Friendswood, Texas.
Receive News & Ratings for Castle Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Castle Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.